REG-4basebio Plc: Joint Development Agreement with Heqet Therapeutics

4BasebioAnnouncement

27/04/2022 07:15

27 April 2022

4basebio PLC

("4basebio", the "Company" or the “Group”)

Joint Development Agreement with Heqet Therapeutics
for development of a non-viral vector therapy for cardiac regeneration

4basebio PLC (AIM: 4BB), the life sciences group focused on exploiting
intellectual property in the field of cell and gene therapies and DNA and mRNA
vaccines, is pleased to announce a Joint Development Agreement (“JDA”)
with Heqet Therapeutics S.r.l. (“Heqet”).  This JDA is focussed on the
development of a non-viral vector, incorporating a proprietary Heqet payload
for cardiomyocyte regeneration and treatment of myocardial infarction more
broadly.

Heqet recently closed an €8m financing round to progress its development
programmes. It is using its proprietary intellectual property to develop
therapies which enable heart regeneration and renewal, thereby avoiding scar
formation on the heart post myocardial infarction. Such scarring can
eventually lead to cardiac dysfunction and failure, despite improvements in
medical interventions. 

Under the JDA, the companies will evaluate the use of 4basebio’s Hermes™
non-viral nanoparticle for the delivery of payloads targeting cardiomyocyte
regeneration.  The successful outcome of this project may lead to the
proof-of-concept development of a therapy enabling heart regeneration post
infarction.

Dr Heikki Lanckriet, CEO and CSO for 4basebio, said: “We are delighted to be
working with Heqet on this novel therapy approach for heart repair following
myocardial infarction. This further demonstrates the flexible application of
our Hermes™ targeted delivery technology within the cell and gene therapy
markets.”

Dr Marta Antonucci, CEO of Heqet, said: “We are delighted to be working
with 4basebio in developing a vector targeting cardiomyocyte regeneration.
4basebio and Heqet bring complementary expertise and technologies to this
exciting program.”

For further enquiries, please contact:

4basebio PLC                     
                               +44 (0)12 2396
7943

Heikki Lanckriet

Nominated Adviser           
                               +44 (0)20 7213
0880

Cairn Financial Advisers LLP

Jo Tuner / Sandy Jamieson

Broker                                 
                              +44 (0)20 7220 0500

finnCap Ltd

Geoff Nash/Richard Chambers/Charlotte Sutcliffe

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic
DNA for cell and gene therapies and DNA vaccines and providing solutions for
effective and safe delivery of these DNA based products to patients. It is the
intention of the Company to become a market leader in the manufacture and
supply of high purity, synthetic DNA for research, therapeutic and
pharmacological use and develop non-viral vectors for the efficient delivery
of payloads. The immediate objectives of 4basebio are to continue the
validation of its DNA products and Hermes™ technology and commence revenue
generation during 2022. 4basebio also continues to advance its collaborations
to facilitate the functional validation of its DNA based products and cell and
gene delivery solutions.

About Heqet

Heqet Therapeutics is an early-stage biotech company focussed on developing
novel RNAi therapeutics to reverse the damage created by ischemic heart
disease, the leading cause of death worldwide. The company is using the
proceeds from its successful financing round to execute its pre-clinical plan
and advance its programs towards clinical application.

Forward-looking statements

This announcement may contain certain statements about the future outlook for
the 4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.



Copyright (c) 2022 PR Newswire Association,LLC. All Rights Reserved